How to select a best-value biological medicine? A practical model to support hospital pharmacists

Liese Barbier, Yannick Vandenplas*, Niels Boone, Isabelle Huys, Rob Janknegt, Arnold G. Vulto

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

6 Downloads (Pure)

Abstract

Purpose With the growing availability of biosimilars on the global market, clinicians and pharmacists have multiple off-patent biological products to choose from. Besides the competitiveness of the product's price, other criteria should be considered when selecting a best-value biological. This article aims to provide a model to facilitate transparent best-value biological selection in the off-patent biological medicines segment. Summary The presented model was developed on the basis of established multicriteria decision analysis tools for rational and transparent medicine selection, ie, the System of Objectified Judgement Analysis and InforMatrix. Criteria for the model were informed by earlier research, a literature search, and evaluation by the authors. The developed model includes up-to-date guidance on criteria that can be considered in selection and provides background on the allocation of weights that may aid hospital pharmacists and clinicians with decision-making in practice. Three main categories of criteria besides price were identified and included in the model: (1) product-driven criteria, (2) service-driven criteria, and (3) patient-driven criteria. Product-driven criteria include technical product features and licensed therapeutic indications. Service-driven criteria consist of supply conditions, value-added services, and environment and sustainability criteria. Patient-driven criteria contain product administration elements such as ease of use and service elements such as patient support programs. Relative weighting of the criteria is largely context dependent and should in a given setting be determined at the beginning of the process. Conclusion The practical model described here may support hospital pharmacists and clinicians with transparent and evidence-based best-value biological selection in clinical practice.
Original languageEnglish
Pages (from-to)2001-2011
Number of pages11
JournalAmerican Journal of Health-System Pharmacy
Volume79
Issue number22
DOIs
Publication statusE-pub ahead of print - 25 Aug 2022

Bibliographical note

© American Society of Health-System Pharmacists 2022.

Fingerprint

Dive into the research topics of 'How to select a best-value biological medicine? A practical model to support hospital pharmacists'. Together they form a unique fingerprint.

Cite this